ElmsL, ShannonS, HughesS, LewisN. Cannabidiol in the treatment of Post-Traumatic Stress Disorder: A case series. JACM, 2019; 25:392–397.
2.
StuytL, HildebrandR. Re: “Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series” by Elms et al. (J Altern Complement Med, 2019; 25:392–397). [Epub ahead of print]; DOI: 10.1089/acm.2019.0380.
3.
GreerGR, GrobCS, HalberstadtAL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs, 2014; 46:73–77.
4.
YanesJA, McKinnellZE, ReidMA, et al.Effects of cannabinoid administration for pain: A meta-analysis and meta-regression. Exp Clin Psychopharmacol, 2019; 27:370–382.
5.
StockingsE, CampbellG, HallWD, et al.Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: A systematic review and meta-analysis of controlled and observational studies. PAIN, 2018; 159:1932–1954.
6.
MückeM, PhillipsT, RadbruchL, et al.Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev, 2018; 3:CD012182.
7.
National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press, 2017. DOI: 10.17226/24625.
8.
HaneyM, EvinsAE. Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharm, 2016; 41:393–401.
9.
UhernikAL, MontoyaZT, BalkissoonCD, SmithJP. Learning and memory is modulated by cannabidiol when administered during trace fear conditioning. Neurobiol Learn Mem, 2018; 149:68–76.
10.
DasRK, KambojSK, RamadasM, et al.Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl), 2013; 226:781–792.
11.
OrsoliniL, ChiappiniS, VolpeU, et al.Use of medicinal cannabis and synthetic cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina (Kaunas), 2019; 55:E525.
12.
BitencourtRM, TakahashiRN. Cannabidiol as a therapeutic alternative for Post-traumatic Stress Disorder: From bench research to confirmation in human trials. Front Neurosci, 2018; 12:502.